# Palbociclib and Cetuximab in Metastatic Colorectal Cancer

> **NCT03446157** · PHASE2 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 24 (actual)

## Conditions studied

- Cancer of the Colon
- Colon Cancer
- Colon Neoplasms
- Colonic Cancer
- Neoplasms, Colonic

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT03446157
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-23
- **Primary completion:** 2023-05-29
- **Final completion:** 2026-01-26
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03446157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03446157, "Palbociclib and Cetuximab in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03446157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*